Arbutus Biopharma Corporation (ABUS) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Arbutus Biopharma (ABUS) Q3 2024: Cash Runway Extends Into Q4 2026 as HBV Functional Cure Programs Advance
November 06, 2024
-
Arbutus Biopharma (ABUS) Q2 2024: 40% Workforce Cut Extends Cash Runway as Phase IIb HBV Focus Intensifies
August 01, 2024
-
Arbutus Biopharma (ABUS) Q1 2024: Cash Runway Extends to 2026 as Combination HBV Trials Advance
May 02, 2024
-
Arbutus Biopharma (ABUS) Q4 2023: Cash Burn Cut 26% as Pipeline Focus Narrows to Hepatitis B Cure
February 29, 2024